The 2025 Endpoints 11 list spotlights 11 private biotech companies driving innovation across AI-powered drug design, in vivo CAR-T therapies, and autoimmune disease treatments. Notable recipients include Chai Discovery harnessing superintelligent AI for drug design, Umoja Biopharma focusing on universal CAR-T cell therapies, and Candid Therapeutics developing novel T-cell engagers for autoimmunity. These ventures have collectively raised over $2 billion, reflecting venture capital enthusiasm for transformative science in oncology, immunology, and neurology. The roster represents the cutting edge of biotech innovation shaping industry directions this year.